N-(2-phenyl-2-hydroxyethyl)-4-(N-Boc-2-aminoethyl)aniline | 321708-64-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-phenyl-2-hydroxyethyl)-4-(N-Boc-2-aminoethyl)aniline
• 英文别名: tert-butyl N-[2-[4-[(2-hydroxy-2-phenylethyl)amino]phenyl]ethyl]carbamate
• CAS: 321708-64-9
• 化学式: C₂₁H₂₈N₂O₃
• 分子量: 356.465
• InChiKey: QTQCZZVKVBAVQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  70.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-phenyl-2-hydroxyethyl)-4-(N-Boc-2-aminoethyl)aniline 在 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 生成 2-[4-(2-amino-ethyl)-phenylamino]-1-phenyl-ethanol
  参考文献：
  名称：

  A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD

  摘要：

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.072
• 作为产物：
  描述：

  2-(4-氨基苯)乙胺 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 N-(2-phenyl-2-hydroxyethyl)-4-(N-Boc-2-aminoethyl)aniline
  参考文献：
  名称：

  A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD

  摘要：

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.072

文献信息

• [EN] beta 2-ADRENERGIC RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RECEPTEURS ADRENERGIQUES DU BETA 2
  申请人：ADVANCED MEDICINE INC

  公开号：WO2001042193A1

  公开（公告）日：2001-06-14

  Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明涉及多重结合化合物，其为β2肾上腺素能受体激动剂，可用于治疗和预防哮喘、支气管炎等呼吸系统疾病。它们还可用于治疗神经系统损伤和早产。
• Beta2-adrenergic receptor agonists
  申请人：Moran J. Edmund

  公开号：US20050261338A1

  公开（公告）日：2005-11-24

  Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明揭示了多重结合化合物，其是β2肾上腺素能受体激动剂，可用于治疗和预防哮喘、支气管炎等呼吸系统疾病。它们也可用于治疗神经系统损伤和早产。
• Methods for identifying novel multimeric agents that modulate receptors
  申请人：——

  公开号：US20030087306A1

  公开（公告）日：2003-05-08

  Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same of different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

  本发明揭示了新型的多重结合化合物（试剂），其能够结合细胞受体。本发明的化合物包括多个配体，每个配体都能够结合到这些细胞受体上，从而调节其生物过程/功能。每个配体均与一个连接剂或连接剂共价结合，这些连接剂可以相同或不同，以提供多重结合化合物。所选择的连接剂使得所构建的多重结合化合物表现出对细胞生物过程/功能的增强调节或干扰。本发明还揭示了一种识别能够结合细胞受体的新型多重结合化合物的方法，以及一种生成这种新型多重结合化合物混合物的方法。
• Beta 2-adrenergic receptor agonists
  申请人：Moran J. Edmund

  公开号：US20060183918A1

  公开（公告）日：2006-08-17

  Disclosed are multibinding compounds which are β2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明涉及多重结合化合物，其是β2-肾上腺素能受体激动剂，并可用于治疗和预防呼吸系统疾病，如哮喘、支气管炎。它们也可用于治疗神经系统损伤和早产。
• &bgr;2-adrenergic receptor agonists
  申请人：Theravance, Inc.

  公开号：US06576793B1

  公开（公告）日：2003-06-10

  Disclosed are multibinding compounds which are &bgr;2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma and bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明涉及一种多重结合化合物，其为&bgr;2肾上腺素受体激动剂，并可用于治疗和预防哮喘和支气管炎等呼吸系统疾病。它们还可用于治疗神经系统损伤和早产。